为认知补充肌酸:对承诺,证据和公众感知的批判性观点
1Independent researcher, Porto Alegre, Rio Grande do Sul, Brazil.
The Journal of nutrition
|July 31, 2025
概括
肌酸作为一种认知增强剂具有前景,但目前的科学证据有限. 这次审查敦促批判性地评估营销声称与科学数据对大脑健康益处的评价.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 补充研究 补充研究
背景情况:
- 肌酸是一种成熟的身体表现补充剂.
- 新兴兴趣突出显示了肌酸作为一种潜在的认知增强剂.
- 显著的公众和商业热情与有限的科学证据形成鲜明对比.
研究的目的:
- 批判性地检查营销叙述和科学证据之间关于肌酸对大脑健康的差距.
- 探索影响肌酸研究解释和传播的认知和结构偏见.
- 倡导加强健康主张传播的批判性评估和透明度.
主要方法:
- 对现有的关于肌酸和认知功能的科学文献进行批判性分析.
- 检查营销趋势和围绕肌酸蛋白的诺特罗普作用潜力的公共话语.
- 探索科学传播中的认知和系统偏见.
主要成果:
- 广泛的说法和对肌酸的认知益处的有限的经验支持之间存在着显著的差异.
- 营销和商业利益可能会超过严格的科学验证.
- 偏见可以扭曲对研究结果的看法和报告.
结论:
- 在评估和传播肌酸所谓的大脑健康益处时,需要更大的批判性评估和透明度.
- 关于肌酸的科学论述应该牢固地建立在强有力的经验数据上.
- 进一步高质量的研究是必要的,以证实认知增强声称.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
208
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
208
Long-term Potentiation
2.9K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.9K
Cognitivism
1.7K
Cognitive psychology emerged as a significant field in the mid-20th century. It focused on understanding humans' internal mental processes. This approach emphasizes how people perceive, remember, think, and solve problems—elements critical to human cognition.
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
1.7K
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Cognitive Development During Adulthood
282
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
282
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262


